Year None202220212020201920182017 Eloxx Pharmaceuticals Announces Changes to Board of Directors July 5, 2022 Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update May 10, 2022 Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update March 31, 2022 Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome March 30, 2022 Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation March 29, 2022
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update May 10, 2022
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update March 31, 2022
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome March 30, 2022
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation March 29, 2022